Literature DB >> 24205871

Functional polymorphisms of TLR8 are associated with hepatitis C virus infection.

Chiou-Huey Wang1, Hock-Liew Eng, Kuei-Hsiang Lin, Hsiang-Chun Liu, Cheng-Hsien Chang, Tsun-Mei Lin.   

Abstract

Chronic hepatitis C virus (HCV) infection is a worldwide threat to public health. Toll-like receptor 8 (TLR8) is critical for eliminating RNA viruses, and variation within the TLR8 gene may alter the function of TLR8 in response to HCV infection. Our previous study demonstrated that the TLR8-129G>C (rs3764879) and TLR8+1G>A (rs3764880) variants were in complete linkage disequilibrium, and that the frequency of TLR8-129C/+1A was significantly higher in male patients with HCV infection compared with the healthy controls. In the present study, we found that the promoter activity of TLR8-129G was higher than that of TLR8-129C in THP-1 cells. Moreover, TLR8-129G mRNA stability and competitive DNA-binding ability were significantly lower than that of TLR8-129C. To investigate the functional effects of TLR8 polymorphisms, we compared the nuclear factor-κB (NF-κB)-driven luciferase activity in HEK293 cells transfected with the TLR8 variants. TLR8+1A plasmids induced less NF-κB signalling than did those transfected with TLR8+1G after 20 μm CL075 (P = 0.011) stimulation. We also analysed the mRNA expression and cytokine production in whole blood and monocytes from people of various genotypes stimulated ex vivo by the interferon-γ and TLR7/8 agonist CL075, R848. TLR8 expression in CD14⁺ cells derived from volunteers with TLR8-129G/+1G was significantly higher than that derived from TLR8-129C/+1A, and interleukin-12p40 production was higher in volunteers with TLR8-129G/+1G after stimulation. The data indicate that variations in TLR8 genes may modulate immune responses during HCV infection.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  Toll-like receptor 8; hepatitis C virus; polymorphisms; promoter; stimulation

Mesh:

Substances:

Year:  2014        PMID: 24205871      PMCID: PMC3956428          DOI: 10.1111/imm.12211

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  28 in total

1.  5'-untranslated regions with multiple upstream AUG codons can support low-level translation via leaky scanning and reinitiation.

Authors:  Xue-Qing Wang; Joseph A Rothnagel
Journal:  Nucleic Acids Res       Date:  2004-02-27       Impact factor: 16.971

Review 2.  Human Toll-like receptor 8 can be cool too: implications for foreign RNA sensing.

Authors:  Soroush T Sarvestani; Bryan R G Williams; Michael P Gantier
Journal:  J Interferon Cytokine Res       Date:  2012-07-20       Impact factor: 2.607

Review 3.  Genetic variation in Toll-like receptors and disease susceptibility.

Authors:  Mihai G Netea; Cisca Wijmenga; Luke A J O'Neill
Journal:  Nat Immunol       Date:  2012-05-18       Impact factor: 25.606

4.  Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8.

Authors:  Keith B Gorden; Kevin S Gorski; Sheila J Gibson; Ross M Kedl; William C Kieper; Xiaohong Qiu; Mark A Tomai; Sefik S Alkan; John P Vasilakos
Journal:  J Immunol       Date:  2005-02-01       Impact factor: 5.422

5.  Cross-talk between programmed death-1 and suppressor of cytokine signaling-1 in inhibition of IL-12 production by monocytes/macrophages in hepatitis C virus infection.

Authors:  Ying Zhang; Cheng J Ma; Lei Ni; Chun L Zhang; Xiao Y Wu; Uday Kumaraguru; Chuan F Li; Jonathan P Moorman; Zhi Q Yao
Journal:  J Immunol       Date:  2011-01-24       Impact factor: 5.422

Review 6.  Polymorphisms of toll-like receptors and their pathways in viral hepatitis.

Authors:  Rohit Sawhney; Kumar Visvanathan
Journal:  Antivir Ther       Date:  2011

7.  HCV core protein interaction with gC1q receptor inhibits Th1 differentiation of CD4+ T cells via suppression of dendritic cell IL-12 production.

Authors:  Stephen N Waggoner; Caroline H T Hall; Young S Hahn
Journal:  J Leukoc Biol       Date:  2007-09-19       Impact factor: 4.962

8.  R-848 triggers the expression of TLR7/8 and suppresses HIV replication in monocytes.

Authors:  Hua Nian; Wen-Qing Geng; Hua-Lu Cui; Ming-jia Bao; Zi-ning Zhang; Min Zhang; Ying Pan; Qing-Hai Hu; Hong Shang
Journal:  BMC Infect Dis       Date:  2012-01-14       Impact factor: 3.090

Review 9.  TLR8: the forgotten relative revindicated.

Authors:  Jorge L Cervantes; Bennett Weinerman; Chaitali Basole; Juan C Salazar
Journal:  Cell Mol Immunol       Date:  2012-10-22       Impact factor: 11.530

10.  Genetic association and expression studies indicate a role of toll-like receptor 8 in pulmonary tuberculosis.

Authors:  Sonia Davila; Martin L Hibberd; Ranjeeta Hari Dass; Hazel E E Wong; Edhyana Sahiratmadja; Carine Bonnard; Bachti Alisjahbana; Jeffrey S Szeszko; Yanina Balabanova; Francis Drobniewski; Reinout van Crevel; Esther van de Vosse; Sergey Nejentsev; Tom H M Ottenhoff; Mark Seielstad
Journal:  PLoS Genet       Date:  2008-10-10       Impact factor: 5.917

View more
  13 in total

Review 1.  Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious diseases.

Authors:  C Skevaki; M Pararas; K Kostelidou; A Tsakris; J G Routsias
Journal:  Clin Exp Immunol       Date:  2015-05       Impact factor: 4.330

2.  TLR8 Couples SOCS-1 and Restrains TLR7-Mediated Antiviral Immunity, Exacerbating West Nile Virus Infection in Mice.

Authors:  Amber M Paul; Dhiraj Acharya; Linda Le; Penghua Wang; Dobrivoje S Stokic; A Arturo Leis; Lena Alexopoulou; Terrence Town; Richard A Flavell; Erol Fikrig; Fengwei Bai
Journal:  J Immunol       Date:  2016-10-21       Impact factor: 5.422

3.  Toll-like receptor polymorphisms in allogeneic hematopoietic cell transplantation.

Authors:  Brian Kornblit; Christian Enevold; Tao Wang; Stephen Spellman; Mike Haagenson; Stephanie J Lee; Klaus Müller
Journal:  Biol Blood Marrow Transplant       Date:  2014-11-20       Impact factor: 5.742

4.  p53-responsive TLR8 SNP enhances human innate immune response to respiratory syncytial virus.

Authors:  Daniel Menendez; Joyce Snipe; Jacqui Marzec; Cynthia L Innes; Fernando P Polack; Mauricio T Caballero; Shepherd H Schurman; Steven R Kleeberger; Michael A Resnick
Journal:  J Clin Invest       Date:  2019-11-01       Impact factor: 14.808

Review 5.  Genetic variants of innate immune receptors and infections after liver transplantation.

Authors:  Gemma Sanclemente; Asuncion Moreno; Miquel Navasa; Francisco Lozano; Carlos Cervera
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

6.  Association of TLR8 and TLR9 polymorphisms with tuberculosis in a Chinese Han population: a case-control study.

Authors:  Ming-Gui Wang; Miao-Miao Zhang; Yu Wang; Shou-Quan Wu; Meng Zhang; Jian-Qing He
Journal:  BMC Infect Dis       Date:  2018-11-13       Impact factor: 3.090

Review 7.  RNA Sensing of Mycobacterium tuberculosis and Its Impact on TB Vaccination Strategies.

Authors:  Sanne Burkert; Ralf R Schumann
Journal:  Vaccines (Basel)       Date:  2020-02-04

Review 8.  Human Genetic Host Factors and Its Role in the Pathogenesis of Chikungunya Virus Infection.

Authors:  Juan C Rueda; Mauricio Arcos-Burgos; Ana M Santos; Daniel Martin-Arsanios; Catalina Villota-Erazo; Viviana Reyes; Santiago Bernal-Macías; Ingris Peláez-Ballestas; Mario H Cardiel; John Londono
Journal:  Front Med (Lausanne)       Date:  2022-02-16

9.  Toll-Like Receptor Family Polymorphisms Are Associated with Primary Renal Diseases but Not with Renal Outcomes Following Kidney Transplantation.

Authors:  Mark C Dessing; Jesper Kers; Jeffrey Damman; Henri G D Leuvenink; Harry van Goor; Jan-Luuk Hillebrands; Bouke G Hepkema; Harold Snieder; Jacob van den Born; Martin H de Borst; Stephan J L Bakker; Gerjan J Navis; Rutger J Ploeg; Sandrine Florquin; Marc Seelen; Jaklien C Leemans
Journal:  PLoS One       Date:  2015-10-07       Impact factor: 3.240

Review 10.  Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.

Authors:  Sacha Gnjatic; Vincenzo Bronte; Laura Rosa Brunet; Marcus O Butler; Mary L Disis; Jérôme Galon; Leif G Hakansson; Brent A Hanks; Vaios Karanikas; Samir N Khleif; John M Kirkwood; Lance D Miller; Dolores J Schendel; Isabelle Tanneau; Jon M Wigginton; Lisa H Butterfield
Journal:  J Immunother Cancer       Date:  2017-05-16       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.